TACE和微波固化消融联合治疗肝细胞癌

Combination therapy with transcatheter arterial chemoembolization and percutanious microwave coagulation for hepatocellular carcinoma

目的探讨TACE和微波固化消融联合治疗肝细胞癌的疗效。方法治疗组：TACE和超声引导下经皮肝穿刺微波消融（PMCT）联合治疗肝细胞癌46例；对照组：TACE治疗肝细胞癌40例。结果治疗组与对照组的1a、2a、3a生存率分别是65％、30％、15％和30％、10％、0，两组之间有显著性差异（P〈0．005）。两组的局部复发率和并发症发生率分别是20％、85％和25％、70％，两组之间比较无显著的统计学意义（x^2=0．013，P=0．6，x^2=1．35，P=0．25）。结论TACE和微波固化消融联合治疗可望成为肝细胞癌的治疗途径之一。

Objective to investigate the efficacy of combination therapy with transcatheter arterial chemoembolization（TACE） and percutanious microwave coagulation therapy（PMCT） for hepatocellular carcinoma（HCC）. Methods 46 patients with HCC were treated by combination therapy with TACE and PMCT in study group, and 40 patients with HCC were treated by TACE in control group. Results One-, two-, three-year cumulative survival rates in study group were markedly higher than control group, 65% vs 30%, 30% vs 10%, and 15% vs 0 respectively （P〈0.005）. The local recurrent and complicational rate had no obvious significance in study group and control group （x^2=0.013, P=0.6, x^2= 1.35, P=0.25）, and they were 20% vs 25% and 85% vs 70%, respectively. Conclusions Combination therapy with TACE and PMCT could be one of the treating approaches for hepatocellular carcinoma.